Compare 8x8 Inc (EGHT) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Immunovant Inc. Common Stock — how do they compare? 8x8 Inc trades at $2.2 (market cap $307.65M), while Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B). The key difference: Immunovant Inc. Common Stock is far larger — about 21.5× 8x8 Inc's market cap, and 8x8 Inc is more actively traded (750,629 versus 1,131,364). Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Immunovant Inc. Common Stock for 0 Days on average.
| EGHT | IMVT | |
|---|---|---|
Market Cap | $307.65M | $6.62B |
Volume | 750,629 | 1,131,364 |
Sector | Technology | Health |
52-Week High | $2.76 | $44.96 |
52-Week Low | $1.59 | $17.03 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $574.57M | $5.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.14, down 1.38% today, with a bullish technical signal from moving averages and strong momentum indicators. The company shows improving fundamentals with three consecutive quarterly EPS beats and projected profitability in 2026. Recent news highlights cost-saving client implementations and AI product growth, while analyst consensus targets $19.77 with mixed ratings.
The outlook suggests potential upside if profitability materializes as projected, supported by operational efficiency gains and AI adoption. Key risks include high debt levels, negative cash flow, and competitive pressures in the communications software sector that could challenge margin expansion.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
